Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Kicks Off Quizartinib Global PIII for 1st-Line AML
October 13, 2016
- Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
October 13, 2016
- Pfizer’s Cancer Research Selected for Feasibility Study under AMED Program; Applied Jointly with Mie Univ. and Other Partners
October 13, 2016
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- Takeda, UK’s Crescendo Cut Collaboration Deal on Cancer Therapeutics
October 12, 2016
- Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
- Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
- Astellas Suits Actavis Elizabeth in US over Myrbetriq Patent
October 11, 2016
- Companion Diagnostics for Opdivo, Keytruda Pending Approval: Agilent Japan Head
October 7, 2016
- Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
October 7, 2016
- Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
October 6, 2016
- GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
October 6, 2016
- Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
October 5, 2016
- Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
October 5, 2016
- Marc van der Heijden to Lead Allergan Japan
October 4, 2016
- Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
October 4, 2016
- Constipation Drug Delivers Positive PIII Data in Japan: EA Pharma, Mochida
October 4, 2016
- Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
October 3, 2016
- Data Out to Support Long-Term Use of Entyvio: Takeda
October 3, 2016
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…